Yes, Cancer Screening is Indicated
A 55-year-old man with membranous nephropathy should undergo age-appropriate cancer screening, as recommended by KDIGO guidelines for all patients with membranous nephropathy, particularly those older than 60 years, though screening should be considered even at age 55. 1
Rationale for Cancer Screening
The association between membranous nephropathy and malignancy is well-established, with cancer incidence significantly elevated compared to the general population (standardized incidence ratio 9.8 for men) 2. While your patient is 55 years old—slightly below the 60-year threshold emphasized in guidelines—the following factors support proactive screening:
Key Risk Indicators
Age and baseline risk: Cancer risk in membranous nephropathy increases progressively with age 2. At 55, this patient is approaching the high-risk age group and warrants consideration for screening.
Diagnostic uncertainty: In 67% of malignancy-associated membranous nephropathy cases, the cancer is unknown at the time of nephropathy diagnosis and only detected through tumor screening 3. This underscores that waiting for clinical signs of malignancy is inadequate.
Pathological Features That Intensify Screening Need
If the kidney biopsy shows any of these features, more intensive screening is warranted 1:
- Subendothelial or mesangial deposits
8 white blood cells per glomerulus (92% sensitivity for malignancy-associated disease) 2
- Non-IgG4 subtype (IgG2 predominance suggests malignancy association) 4
- Negative PLA2R staining (only 37.9% of malignancy-associated cases are PLA2R-positive versus 85% of idiopathic cases) 4, 3
- Positive THSD7A staining (more frequently associated with malignancy) 4, 5
Recommended Screening Approach
Perform age-appropriate cancer screening following standard guidelines for a 55-year-old man, which typically includes:
- Colonoscopy (if not recently completed)
- Lung cancer screening if smoking history meets criteria
- Prostate cancer discussion based on shared decision-making
Additional considerations based on membranous nephropathy-specific risks:
- Solid organ malignancies are most common (lung, gastrointestinal, genitourinary, prostate) 3, 5
- Consider CT chest/abdomen/pelvis if high-risk pathological features are present
- Hematologic malignancies are less common but possible
Clinical Pitfalls to Avoid
Do not assume idiopathic disease without screening: Even in PLA2R-positive cases, malignancy can coexist 6. The absence of typical secondary features does not exclude cancer-associated disease.
Monitor treatment response: Poor response to immunosuppressive therapy or unexpected recurrence of proteinuria should trigger repeat malignancy screening 7. Some patients develop cancer after initial membranous nephropathy diagnosis.
Smoking history matters: Smoking is significantly more frequent in patients with cancer-associated membranous nephropathy 2, making screening even more critical if your patient has this risk factor.
Impact on Outcomes
This recommendation prioritizes mortality reduction, as 25% of patients with malignancy-associated membranous nephropathy die over median 24-month follow-up, primarily from cancer 3. Early cancer detection allows for: